Related Experiment Video

Updated: Jun 6, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

Targeting non-malignant disorders with tyrosine kinase inhibitors

Friedrich Grimminger1, Ralph T Schermuly, Hossein A Ghofrani

  • 1University Hospital Giessen and Marburg, Medical Clinic II/IV/V, Klinikstrasse 36, 35398 Giessen, Germany.

Nature Reviews. Drug Discovery
|December 2, 2010
PubMed

Insights

Tyrosine kinase inhibitors (TKIs) show promise beyond cancer treatment. This review explores their potential therapeutic applications in various non-malignant and benign-proliferative disorders.

Area of Science:

  • Biochemistry
  • Pharmacology
  • Oncology

Background:

  • Receptor and non-receptor tyrosine kinases regulate critical proliferative signaling pathways.
  • Tyrosine kinase inhibitors (TKIs) have transformed cancer therapy, notably chronic myelogenous leukemia with imatinib.
  • TKIs are approved for treating various cancers, including renal cell carcinoma, non-small-cell lung cancer, and colon cancer.

Purpose of the Study:

  • To review recent experimental and clinical developments in the therapeutic potential of TKIs.
  • To explore the application of TKIs in non-malignant disorders.
  • To highlight emerging roles for TKIs in benign-proliferative conditions.

Main Methods:

  • Literature review of recent experimental studies.
  • Analysis of clinical trial data.
  • Synthesis of findings on TKI efficacy and safety in non-malignant conditions.

Main Results:

  • TKIs demonstrate potential as anti-proliferative agents in non-malignant conditions.
  • Evidence supports TKI use in cardiac hypertrophy, pulmonary hypertension, and lung fibrosis.
  • TKIs are being investigated for rheumatoid disorders, atherosclerosis, in-stent restenosis, and glomerulonephritis.

Conclusions:

  • TKIs offer a promising therapeutic avenue for a range of non-malignant disorders.
  • Further research and clinical trials are warranted to fully establish TKI efficacy and safety in these conditions.
  • The scope of TKI application is expanding beyond oncology into broader therapeutic areas.

More Related Videos

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...